Royalty Pharma plc Class A Ordinary Shares
Symbol: RPRX (NASDAQ)
Company Description:
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Today's Open: $36.6
- Today's High: $36.669
- Today's Low: $35.431
- Today's Volume: 2.21M
- Yesterday Close: $36.49
- Yesterday High: $36.6
- Yesterday Low: $36.15
- Yesterday Volume: 2.83M
- Last Min Volume: 0
- Last Min High: $36.049
- Last Min Low: $35.904
- Last Min VWAP: $0
- Name: Royalty Pharma plc Class A Ordinary Shares
- Website: https://www.royaltypharma.com
- Listed Date: 2020-06-16
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001802768
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $15.77B
- Round Lot: 100
- Outstanding Shares: 432.29M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-30 | 4 | View |
2025-09-16 | 8-K | View |
2025-09-03 | 424B2 | View |
2025-09-03 | FWP | View |
2025-09-02 | 424B2 | View |
2025-09-02 | POSASR | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-13 | 8-K | View |
2025-08-13 | SCHEDULE 13G | View |
2025-08-11 | 4 | View |
2025-08-11 | 144 | View |
2025-08-08 | 4 | View |
2025-08-08 | 4 | View |
2025-08-08 | 4 | View |
2025-08-08 | 4 | View |
2025-08-08 | 4 | View |
2025-08-06 | 10-Q | View |
2025-08-06 | 8-K | View |
2025-08-05 | SCHEDULE 13G/A | View |
2025-07-31 | 4 | View |